PROMUS PREMIER™ China Post-Approval Study
NCT03273023 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2059
Last updated 2026-03-31
Summary
To compile real-world clinical outcome data for the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System (Promus PREMIERTM Stent System) in routine clinical practice in China.
Conditions
Interventions
- DEVICE
-
Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System
Promus PREMIERTM Stent System
Sponsors & Collaborators
-
Boston Scientific Corporation
lead INDUSTRY
Principal Investigators
-
Bo Yu, Dr. · The Second Affiliated Hospital of Harbin Medical University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-11
- Primary Completion
- 2020-12-28
- Completion
- 2025-10-03
Countries
- China
Study Locations
More Related Trials
-
A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China
NCT03736226 ·Status: ACTIVE_NOT_RECRUITING
-
Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent
NCT01233453 ·Status: UNKNOWN ·Phase: PHASE4
-
Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization
NCT01342822 ·Status: UNKNOWN
-
PROMUS Element Plus US Post-Approval Study
NCT01589978 ·Status: COMPLETED ·Phase: PHASE4
-
XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan
NCT01086228 ·Status: COMPLETED
-
PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study
NCT01148329 ·Status: COMPLETED
-
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels
NCT01498692 ·Status: COMPLETED ·Phase: NA
-
China Resolute Integrity 34/38 mm Study
NCT03118531 ·Status: COMPLETED ·Phase: NA
-
XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)
NCT02513719 ·Status: COMPLETED
-
Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)
NCT02452736 ·Status: COMPLETED ·Phase: PHASE3
-
PROGRESS-AMS 1.0 Clinical Long Term Follow-Up
NCT01610102 ·Status: COMPLETED
-
A First-in-Man Study of IBS
NCT03509142 ·Status: COMPLETED ·Phase: NA
-
A First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System
NCT03616132 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)
NCT02698852 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
NCT01721096 ·Status: COMPLETED
-
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen
NCT01267734 ·Status: UNKNOWN ·Phase: PHASE4
-
BIOFLOW-china Post-marketing Study (BIOTRONIK)
NCT05667285 ·Status: TERMINATED
-
Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing
NCT00698607 ·Status: COMPLETED ·Phase: PHASE4
-
Xience/Promus for Long Coronary Lesion Registry
NCT01147237 ·Status: UNKNOWN ·Phase: PHASE4
-
Promus - Registry Experience at the Washington Hospital Center, Drug-eluting Stent (DES)
NCT01003795 ·Status: WITHDRAWN
-
Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents for Long-Coronary Lesions
NCT01186120 ·Status: COMPLETED ·Phase: PHASE4
-
Long Term Efficacy and Safety of Firebird Sirolimus-Eluting Stent In Complex Coronary Lesions
NCT00552656 ·Status: UNKNOWN
-
IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease
NCT04849325 ·Status: UNKNOWN ·Phase: NA
-
LEADERS FREE IV (RCT): BioFreedom™ Ultra vs BioFreedom™ in HBR Patients
NCT06657326 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Effectiveness and Safety of PROMUS Element Stent (IRIS-ELEMENT )
NCT01350791 ·Status: COMPLETED